亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma

医学 阿替唑单抗 威罗菲尼 内科学 肿瘤科 贝伐单抗 神经母细胞瘤RAS病毒癌基因同源物 克拉斯 队列 靶向治疗 易普利姆玛 癌症 结直肠癌 彭布罗利珠单抗 化疗 免疫疗法 转移性黑色素瘤
作者
Maria E. Cabanillas,Ramona Dadu,Renata Ferrarotto,Maria Gule-Monroe,Suyu Liu,Bryan Fellman,Michelle D. Williams,Mark Zafereo,Jennifer Wang,Charles Lu,Matthew S. Ning,Brian McKinley,Scott E. Woodman,Dzifa Y. Duose,G. Brandon Gunn,Naifa L. Busaidy,Ahmed Al-Rawi,Claudio A. Arrechedera,Kelsey Ayers,Claudia Bedoya
出处
期刊:JAMA Oncology [American Medical Association]
被引量:20
标识
DOI:10.1001/jamaoncol.2024.4729
摘要

Importance Anaplastic thyroid carcinoma (ATC) is a rare and lethal cancer. Although progress has been made in recent years in patients with mutated BRAF tumors, those who respond initially eventually die of their disease; furthermore, there are no approved therapies for non-BRAF mutated tumors. Objective To determine whether treatment with matched-targeted therapy plus immune checkpoint inhibitors were associated with improved overall survival (OS). Design, Setting, and Participants A phase 2 trial at a single center, tertiary institution with parallel cohorts, assigning treatment with targeted therapy according to the tumor mutation status. Patients with mutated BRAF V600E tumors received vemurafenib/cobimetinib plus atezolizumab (cohort 1); those with mutated RAS (NRAS, KRAS, or HRAS) or NF1/2 tumors received cobimetinib plus atezolizumab (cohort 2). Patients without any of these variants were assigned to receive bevacizumab plus atezolizumab (cohort 3). Patients were enrolled from August 3, 2017, to July 7, 2021. All consecutive, systemic therapy-naive patients with ATC with active disease and who met eligibility criteria were considered for participation. The analysis was conducted in September 2023. Interventions Patients were assigned to targeted therapy based on the driver mutation as follow: BRAF V600E (cohort 1, vemurafenib plus cobimetinib), RAS/NF (cohort 2, cobimetinib), or non- BRAF / RAS / NF (cohort 3, bevacizumab). All received atezolizumab. Main Outcomes and Measures The primary outcome of the study was median OS of the entire targeted therapy cohort, compared with historical median OS of 5 months. Results Forty-three patients with ATC were enrolled in the targeted therapy cohorts, of which 42 were included in the primary analysis. The median OS in patients across these 3 cohorts was 19 months (95% CI, 7.79-43.24). Median OS and progression-free survival per cohort were as follows: cohort 1: 43 months (95% CI, 16-not estimable [NE]), 13.9 months (6.6-64.1); cohort 2: 8.7 months (95% CI, 5.1-37.0) and 4.8 months (1.8-14.7); cohort 3 (vascular endothelial growth factor inhibitor group): 6.21 months (4.1-NE) and 1.3 months (1.3-NE), respectively. Conclusions and Relevance In this nonrandomized clinical trial, atezolizumab combined with targeted therapy resulted in a longer median OS than historical landmark, achieving the study’s primary end point, with cohort 1 achieving the longest OS. Trial Registration ClinicalTrials.gov Identifier: NCT03181100
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
u615138发布了新的文献求助10
1秒前
u131815发布了新的文献求助10
1秒前
1秒前
2秒前
2秒前
u615138发布了新的文献求助10
4秒前
u615138发布了新的文献求助10
4秒前
4秒前
5秒前
u834401发布了新的文献求助10
6秒前
7秒前
7秒前
英俊的铭的应助被LJH采纳,获得10
7秒前
9秒前
u834401发布了新的文献求助10
9秒前
u588294发布了新的文献求助10
9秒前
u588294发布了新的文献求助10
9秒前
10秒前
11秒前
u314510发布了新的文献求助10
12秒前
u314510发布了新的文献求助10
12秒前
u216593发布了新的文献求助10
12秒前
u216593发布了新的文献求助10
12秒前
14秒前
15秒前
u245792发布了新的文献求助10
15秒前
u488353发布了新的文献求助10
15秒前
u245792发布了新的文献求助10
15秒前
15秒前
16秒前
16秒前
u360016发布了新的文献求助10
18秒前
u620348发布了新的文献求助10
18秒前
u360016发布了新的文献求助10
18秒前
19秒前
20秒前
21秒前
u266829发布了新的文献求助10
21秒前
u996067发布了新的文献求助10
21秒前
烂漫亦巧完成签到,获得积分10
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185137
求助须知:如何正确求助?哪些是违规求助? 9574052
关于积分的说明 21834040
捐赠科研通 7782575
什么是DOI,文献DOI怎么找? 3434520
关于科研通互助平台的介绍 2558743
邀请新用户注册赠送积分活动 2481206